140 related articles for article (PubMed ID: 15624289)
41. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy.
ter Horst PG; Larmené-Beld KH; Bosman J; van der Veen EL; Wieringa A; Smit JP
J Clin Pharm Ther; 2014 Oct; 39(5):541-4. PubMed ID: 24989434
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Juan H; Zhiling Z; Huande L
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jun; 820(1):33-9. PubMed ID: 15866490
[TBL] [Abstract][Full Text] [Related]
43. Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study.
Patel BN; Sharma N; Sanyal M; Shrivastav PS
J Pharm Biomed Anal; 2008 Jul; 47(3):603-11. PubMed ID: 18387768
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals.
Howell SR; Hicks DR; Scatina JA; Sisenwine SF
Xenobiotica; 1994 Apr; 24(4):315-27. PubMed ID: 8059535
[TBL] [Abstract][Full Text] [Related]
45. Three-phase, liquid-phase microextraction combined with high performance liquid chromatography-fluorescence detection for the simultaneous determination of fluoxetine and norfluoxetine in human plasma.
de Freitas DF; Porto CE; Vieira EP; de Siqueira ME
J Pharm Biomed Anal; 2010 Jan; 51(1):170-7. PubMed ID: 19683889
[TBL] [Abstract][Full Text] [Related]
46. Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
Wille SM; Maudens KE; Van Peteghem CH; Lambert WE
J Chromatogr A; 2005 Dec; 1098(1-2):19-29. PubMed ID: 16314157
[TBL] [Abstract][Full Text] [Related]
47. A simple HPLC method for the simultaneous determination of venlafaxine and its major metabolite O-desmethylvenlafaxine in human serum.
Samanidou V; Nazyropoulou C; Kovatsi L
Bioanalysis; 2011 Aug; 3(15):1713-8. PubMed ID: 21827270
[TBL] [Abstract][Full Text] [Related]
48. Distribution of venlafaxine and O-desmethylvenlafaxine in a fatal case.
Vignali C; Morini L; Chen Y; Stramesi C; Groppi A
Forensic Sci Int; 2014 Sep; 242():e48-e51. PubMed ID: 25086830
[TBL] [Abstract][Full Text] [Related]
49. Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction.
Kingbäck M; Josefsson M; Karlsson L; Ahlner J; Bengtsson F; Kugelberg FC; Carlsson B
J Pharm Biomed Anal; 2010 Nov; 53(3):583-90. PubMed ID: 20435422
[TBL] [Abstract][Full Text] [Related]
50. Determination of venlafaxine and its active metabolite O-desmethylvenlafaxine in human plasma by HPLC fluorescence.
Shen S; Zhang C; Mao Y
Gen Psychiatr; 2018; 31(2):e000010. PubMed ID: 30582123
[TBL] [Abstract][Full Text] [Related]
51. Simultaneous separation and determination of process-related substances and degradation products of venlafaxine by reversed-phase HPLC.
Nageswara Rao R; Narasa Raju A
J Sep Sci; 2006 Dec; 29(18):2733-44. PubMed ID: 17305234
[TBL] [Abstract][Full Text] [Related]
52. Chiral HPLC analysis of venlafaxine metabolites in rat liver microsomal preparations after LPME extraction and application to an in vitro biotransformation study.
da Fonseca P; Bonato PS
Anal Bioanal Chem; 2010 Jan; 396(2):817-24. PubMed ID: 19937433
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients.
Godoy AL; Rocha A; da Silva Souza C; Lanchote VL
J Clin Pharmacol; 2016 May; 56(5):567-75. PubMed ID: 26331791
[TBL] [Abstract][Full Text] [Related]
54. The effect of renal disease on the disposition of venlafaxine.
Troy SM; Schultz RW; Parker VD; Chiang ST; Blum RA
Clin Pharmacol Ther; 1994 Jul; 56(1):14-21. PubMed ID: 8033490
[TBL] [Abstract][Full Text] [Related]
55. Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine.
Asafu-Adjaye EB; Faustino PJ; Tawakkul MA; Anderson LW; Yu LX; Kwon H; Volpe DA
J Pharm Biomed Anal; 2007 Apr; 43(5):1854-9. PubMed ID: 17300896
[TBL] [Abstract][Full Text] [Related]
56. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
[TBL] [Abstract][Full Text] [Related]
57. A Massive Venlafaxine Intoxication: Evolution of Cardiac Toxicity with Venlafaxine and O-Desmethylvenlafaxine Elimination Kinetics: A Grand Round.
Couderc S; Gabriel A; Decheiver S; N'Zoué Kanga S; Fikanni A; Flint H; Pihan F; Sahar A; Tifrea M; Tifrea A; Marsaud JP; Vandroux D
Ther Drug Monit; 2024 Apr; 46(2):133-137. PubMed ID: 38158602
[TBL] [Abstract][Full Text] [Related]
58. Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles.
Zhu YL; Li SL; Chen KL; Ma KP; Wu DQ; Qiu XJ
Drug Des Devel Ther; 2019; 13():3343-3355. PubMed ID: 31571835
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships.
Hansen MR; Kuhlmann IB; Pottegård A; Damkier P
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):298-302. PubMed ID: 28397349
[TBL] [Abstract][Full Text] [Related]
60. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
